Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency



Status:Archived
Conditions:Chronic Obstructive Pulmonary Disease, Pulmonary
Therapuetic Areas:Pulmonary / Respiratory Diseases
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:November 2010
End Date:August 2011

Use our guide to learn which trials are right for you!

A Randomized Double-blind Crossover Study to Assess the Safety and Pharmacokinetics of Two Different Doses of Weekly Intravenous Administration of Alpha1-Proteinase Inhibitor (Human) Prolastin-C in Subjects With Alpha1-Antitrypsin Deficiency


This is a study to assess the safety and pharmacokinetics of weekly infusions of 120 mg/kg
of Alpha-1 PI, compared to weekly infusions of 60 mg/kg of Alpha-1 PI in patients with alpha
1-antitrypsin deficiency (AATD).


The question of whether higher doses of Alpha-1 PI (>60 mg/kg) are able to provide better
protection to patients with alpha 1-antitrypsin deficiency is currently unknown. As a first
step to address this question, the present study has been undertaken. This is a
multi-center, randomized, double-blind, crossover study to assess the safety and
pharmacokinetics of weekly infusions of 120 mg/kg of Alpha-1 PI, compared to weekly
infusions of 60 mg/kg of Alpha-1 PI in patients with alpha 1-antitrypsin deficiency. This
study is a crossover design with 2 treatment sequences:

Treatment Sequence 1: 60 mg/kg weekly infusion of Alpha-1 PI for 8 weeks followed by 120
mg/kg weekly infusion of Alpha-1 PI for 8 weeks (starting at Week 1) (total of 16 treatment
weeks)

Treatment Sequence 2: 120 mg/kg weekly infusion of Alpha-1 PI for 8 weeks followed by 60
mg/kg weekly infusion of Alpha-1 PI for 8 weeks (starting at Week 11) (total of 16 treatment
weeks)

Approximately 15 subjects are planned to be entered into each treatment sequence.

At Weeks 8 to 11 and Weeks 18 to 21, a total of 15 serial blood samples for each subject
will be drawn for pharmacokinetic analysis. The expected duration of the study subject's
participation will be approximately 25 weeks (which includes a 3-Week Screening Phase,
2-Week Washout Period [between different alpha-1 PI treatment doses], and a 4-Week Follow-up
Period). The following safety parameters will be assessed: adverse events, pulmonary
exacerbations, vital signs, pulmonary function tests, and clinical laboratory tests.


We found this trial at
5
sites
Gainesville, Florida 32611
(352) 392-3261
University of Florida Gainesville UF has a long history of established programs in international education,...
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
843-792-1414
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
?
mi
from
Charleston, SC
Click here to add this to my saved trials
1400 NW 12th Ave
Miami, Florida 33136
(305) 689-5511
University of Miami Hospital The University of Miami changed the face of modern health care...
?
mi
from
Miami, FL
Click here to add this to my saved trials
1801 N Broad St
Philadelphia, Pennsylvania 19122
(215) 204-7000
Temple University Temple University is many things to many people. A place to pursue life's...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
?
mi
from
San Antonio, TX
Click here to add this to my saved trials